Gastric Carcinoma — Trials

Gastric Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

586 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 183
Recruiting: 93
Ph III recruiting: 15
Growth YoY: +4.3%
Industry share: 21%
Top sponsor: National Cancer Institute (NCI)
Termination share: 33.3%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (65)

clinicaltrialsPublishedShowing 101–101 of 101 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT05190445	Cinrebafusp Alfa in Combination With Ramucirumab and Paclitaxel in HER2-High Gastric or GEJ Adenocarcinoma and in Combination With Tucatinib in HER2-Low Gastric or GEJ Andenocarinoma	active not recruiting	Phase 2	80	Pieris Pharmaceuticals, Inc.INDUSTRY	2	Sep 8, 2022	clinicaltrials